EX-99.1 2 ex99-1.htm EX-99.1

NEWS RELEASE
   
  CONTACT:
  CONMED Corporation
  Robert Shallish
  Chief Financial Officer
  315-624-3206

 

 

FOR RELEASE: 7:00 AM (Eastern) July 24, 2013

 

CONMED Corporation Announces Second Quarter 2013 Financial Results

- EPS equals $0.34

- Adjusted EPS equals $0.43

 

Conference Call to be Held at 10:00 a.m. ET Today

 

 

Utica, New York, July 24, 2013 ----- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the second quarter ended June 30, 2013.

 

“We met our previously forecasted revenues and earnings in the second quarter of 2013 despite a challenging global economy affecting healthcare utilization and hospital capital spending,” commented Mr. Joseph J. Corasanti, President and CEO. “Having a broad product portfolio such as ours is extremely beneficial in this environment. It allows us to meet our customers’ needs and to take advantage of opportunities as evidenced by the strong showing this quarter in the Surgical Visualization product line.”

 

Second Quarter 2013 Financial Highlights:

 

·Sales were $193.0 million, an increase of 1.7% (0.1% organic) and 2.3% in constant currency over the second quarter of 2012

 

·Diluted earnings per share (GAAP) were $0.34 compared to $0.36 in the second quarter of 2012 (excluding the medical device excise tax or “MDET,” EPS would have been $0.37 in 2013)

 

·Adjusted diluted earnings per share were $0.43 in the second quarters of both years (excluding the MDET, adjusted EPS would have been $0.46 in 2013)

 

·Adjusted EBITDA margin was 16.9%, a decrease of 20 basis points, caused by a 70 basis point negative effect from the MDET offset by operating improvements

 

Six Months 2013 Financial Highlights

 

·Sales were $380.0 million compared to $384.0 million, a decrease of 1.0% (decrease of 2.2% organic) and a decrease of 0.5% in constant currency

 

·Diluted earnings per share (GAAP) were $0.71 in both six month periods (excluding the MDET, EPS would have been $0.78 in 2013)

 

·Adjusted diluted earnings per share grew to $0.88 compared to $0.85 in the first six months of 2012 (excluding the MDET, EPS would have been $0.94 in 2013)

 

 
CONMED News Release ContinuedPage 2 of 12July 24, 2013

·Adjusted EBITDA margin was 17.0%, a decrease of 10 basis points, even with an 80 basis point negative effect from the MDET offset by operating improvements

 

 

International sales in the second quarter of 2013 were $100.0 million, representing 51.8% of total sales. Foreign currency exchange rates including the effects of the FX hedging program caused sales to be $1.1 million less in the second quarter of 2013 compared to sales in the second quarter of 2012.

 

Cash provided by operating activities increased sequentially from the first quarter 2013 and equaled $17.7 million. For the six months ended June 2013, cash provided by operating activities was $23.2 million. The Company repurchased 582,000 shares of its common stock in the second quarter of 2013 and 1,431,000 shares in the first half of 2013 for $19.0 million and $44.7 million, respectively.

 

Outlook

 

“As we look to the rest of 2013, we anticipate continuation of current healthcare trends represented by flat to slightly negative healthcare utilization in the U.S. combined with governmental spending controls in major European countries. While we believe there may be slight moderation of these trends toward the end of 2013, we believe it prudent to tighten our full year 2013 adjusted earnings per share guidance by reducing the top end of the previous guidance range to $1.80 - $1.85 from the former $1.80 - $1.90 per share. This forecast contemplates the effects of the medical device tax and less favorable FX exchange rates,” said Mr. Corasanti. “Similarly, we now tighten the forecasted sales range to $770 - $775 million from the prior $770 - $780 million.”

 

“For the third quarter of 2013, we anticipate sales will approximate $184 - $189 million and adjusted earnings per share are forecasted to be $0.37 - $0.42,” continued Mr. Corasanti.

 

The adjusted estimates for the third quarter and full year 2013 exclude special items, such as manufacturing restructuring costs expected to be incurred in 2013 due to the relocation of manufacturing activities from the Westborough, Massachusetts and Tampere, Finland sites to the Company’s other facilities and patent litigation.

 

Special charges

 

During the second quarter of 2013, the Company continued the on-going consolidation of certain administrative functions and manufacturing activities. Also incurred were litigation costs associated with a patent matter. Expenses associated with these activities, including severance and relocation costs, amounted to $2.4 million, net of tax, in the second quarter of 2013. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2013, the Company presently anticipates incurring additional pre-tax special costs of $6.5 - $7.5 million on projects currently in process.

 

Use of non-GAAP financial measures

 

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company’s on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income, adjusted operating income and adjusted earnings per share measure the income of the Company excluding credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income, adjusted operating margin and adjusted earnings per share because management believes that in order to properly understand the Company’s short and long-term financial trends, the impact of special items should be eliminated from on-going operating activities. These adjustments for special items are derived from facts and circumstances that vary in frequency and impact on the Company’s results of operations. Management uses adjusted net income, adjusted operating income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

 

 
CONMED News Release ContinuedPage 3 of 12July 24, 2013

 

Conference call

 

The Company will webcast its second quarter 2013 conference call live over the Internet at 10:00 a.m. Eastern Time on Wednesday, July 24, 2013. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through August 2, 2013.

 

 

CONMED profile

 

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company’s total sales.

 

 

Forward Looking Information

 

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation of litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company’s ability to devise and execute strategies to respond to market conditions.

 

 
CONMED News Release ContinuedPage 4 of 12July 24, 2013

 

CONMED CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(In thousands except per share amounts)

(unaudited)

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2012   2013   2012   2013 
                 
Net sales  $189,695   $192,993   $384,011   $380,007 
Cost of sales   88,761    88,471    180,692    171,181 
Cost of sales, other – Note A   1,202    1,606    2,676    3,228 
                     
Gross profit   99,732    102,916    200,643    205,598 
                     
Selling and administrative   73,707    77,174    148,513    154,899 
Research and development   7,192    6,591    14,287    12,285 
Medical device excise tax   —    1,406    —    2,986 
Other expense– Note B   1,775    2,093    3,763    3,906 
    82,674    87,264    166,563    174,076 
                     
Income from operations   17,058    15,652    34,080    31,522 
                     
Loss on early extinguishment of debt   —    —    —    263 
                     
Interest expense   1,551    1,383    2,988    2,749 
                     
Income before income taxes   15,507    14,269    31,092    28,510 
                     
Provision for income taxes   5,211    4,736    10,828    8,485 
                     
Net income  $10,296   $9,533   $20,264   $20,025 
                     
Per share data:                    
Net income                    
Basic  $.36   $.35   $.72   $.72 
Diluted   .36    .34    .71    .71 
                     
Weighted average common shares                    
Basic   28,327    27,591    28,178    27,860 
Diluted   28,672    27,983    28,577    28,258 

 

 

Note A –Included in cost of sales, other in the three and six months ended June 30, 2012 and 2013 are costs related to the consolidation of our production facilities. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.

 

Note B – Other expense in the three and six months ended June 30, 2012 and 2013 includes a number of adjusted charges. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.

 

 
CONMED News Release ContinuedPage 5 of 12July 24, 2013

 

CONMED CORPORATION

CONSOLIDATED CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

ASSETS

 

   December 31,   June 30, 
   2012   2013 
Current assets:          
Cash and cash equivalents  $23,720   $38,123 
Accounts receivable, net   139,124    140,570 
Inventories   156,228    148,717 
Income taxes receivable   2,897    2,800 
Deferred income taxes   11,931    10,548 
Prepaid expenses and other current assets   14,993    17,848 
Total current assets   348,893    358,606 
           
Property, plant and equipment, net   139,041    137,612 
Deferred income taxes   1,057    1,166 
Goodwill   249,160    249,160 
Other intangible assets, net   190,809    186,823 
Other assets   150,547    149,653 
Total assets  $1,079,507   $1,083,020 
           
LIABILITIES AND SHAREHOLDERS' EQUITY
           
Current liabilities:          
Current portion of long-term debt  $1,050   $1,093 
Other current liabilities   124,164    98,062 
Total current liabilities   125,214    99,155 
           
Long-term debt   160,802    233,017 
Deferred income taxes   99,857    105,630 
Other long-term liabilities   86,636    60,551 
Total liabilities   472,509    498,353 
           
Shareholders' equity:          
Capital accounts   256,672    223,899 
Retained earnings   377,907    389,620 
Accumulated other comprehensive loss   (27,581)   (28,852)
Total equity   606,998    584,667 
           
Total liabilities and shareholders' equity  $1,079,507   $1,083,020 

 

 
CONMED News Release ContinuedPage 6 of 12July 24, 2013

CONMED CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

   Six months ended 
   June 30, 
   2012   2013 
Cash flows from operating activities:          
Net income  $20,264   $20,025 
Adjustments to reconcile net income          
to net cash provided by operating activities:          
Depreciation and amortization   23,064    23,816 
Stock-based compensation   2,574    2,496 
Loss on early extinguishment of debt   —    263 
Deferred income taxes   6,091    5,038 
Increase (decrease) in cash flows from changes in assets and liabilities:          
Accounts receivable   (1,027)   (2,689)
Inventories   3,078    (1,581)
Accounts payable   1,345    (2,207)
Income taxes receivable (payable)   (4,589)   (1,171)
Accrued compensation and benefits   (6,730)   (7,393)
Other assets   (1,779)   (3,714)
Other liabilities   (9,014)   (9,729)
Net cash provided by operating activities   33,277    23,154 
           
Cash flows from investing activities:          
Payments related to distribution agreement   (64,116)   — 
Purchases of property, plant, and equipment   (11,596)   (8,201)
Net cash used in investing activities   (75,712)   (8,201)
           
Cash flows from financing activities:          
Payments on debt   (32,538)   (742)
Proceeds of debt   57,000    73,000 
Payments related to distribution agreement   —    (34,000)
Dividends paid on common stock   (4,328)   (8,445)
Payments related to issuance of debt   —    (1,725)
Net proceeds from common stock issued under employee plans   7,868    10,366 
Repurchase of common stock   —    (44,729)
Other, net   4,925    7,090 
Net cash provided by financing activities   32,927    815 
           
Effect of exchange rate change on cash and cash equivalents   (294)   (1,365)
           
Net increase (decrease) in cash and cash equivalents   (9,802)   14,403 
           
Cash and cash equivalents at beginning of period   26,048    23,720 
           
Cash and cash equivalents at end of period  $16,246   $38,123 
 
CONMED News Release ContinuedPage 7 of 12July 24, 2013

 

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME

Three Months Ended June 30, 2012 and 2013

(In thousands except per share amounts)

(unaudited)

 

   2012   2013 
         
Reported net income  $10,296   $9,533 
           
Facility consolidation costs included in cost of sales   1,202    1,606 
           
Administrative consolidation costs included in other expense   1,231    1,566 
           
Legal arbitration and patent dispute costs included in other expense   544    527 
           
Total other expense   1,775    2,093 
           
Adjusted expense before income taxes   2,977    3,699 
           
Provision (benefit) for income taxes on adjusted expenses   (1,072)   (1,332)
           
Adjusted net income  $12,201   $11,900 
           
           
Per share data:          
           
Reported net income          
Basic  $0.36   $0.35 
Diluted   0.36    0.34 
           
Adjusted net income          
Basic  $0.43   $0.43 
Diluted   0.43    0.43 

 

Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above.

 
CONMED News Release ContinuedPage 8 of 12July 24, 2013

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME

Six Months Ended June 30, 2012 and 2013

(In thousands except per share amounts)

(unaudited)

 

   2012   2013 
         
Reported net income  $20,264   $20,025 
           
Facility consolidation costs included in cost of sales   2,676    3,228 
           
Administrative consolidation costs included in other expense   1,504    3,170 
           
Costs associated with purchase of Nordic region distributor   704    — 
           
Legal arbitration and patent dispute costs included in other expense   1,555    736 
           
Total other expense   3,763    3,906 
           
Loss on early extinguishment of debt   —    263 
           
Adjusted expense before income taxes   6,439    7,397 
           
Provision (benefit) for income taxes on adjusted expenses   (2,318)   (2,663)
           
Adjusted net income  $24,385   $24,759 
           
           
Per share data:          
           
Reported net income          
Basic  $0.72   $0.72 
Diluted   0.71    0.71 
           
Adjusted net income          
Basic  $0.87   $0.89 
Diluted   0.85    0.88 

 

Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above.

 

 
CONMED News Release ContinuedPage 9 of 12July 24, 2013

 

CONMED CORPORATION

RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED INCOME FROM OPERATIONS

(In thousands)

(unaudited)

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2012   2013   2012   2013 
                 
Reported income from operations  $17,058   $15,652   $34,080   $31,522 
                     
Facility consolidation costs included in cost of sales   1,202    1,606    2,676    3,228 
                     
Administrative consolidation costs included in other expense   1,231    1,566    1,504    3,170 
                     
Medical device excise tax   —    1,406    —    2,986 
                     
Costs associated with purchase of Nordic region distributor   —    —    704    — 
                     
Legal arbitration and patent dispute costs included in other expense   544    527    1,555    736 
                     
Adjusted income from operations  $20,035   $20,757   $40,519   $41,642 
                     
Operating Margin                    
Reported   9.0%    8.1%    8.9%    8.3% 
                     
Adjusted   10.6%    10.8%    10.6%    11.0% 

 

 

Management has provided the above reconciliation as an additional measure that investors can use to compare financial results between reporting periods. Management believes this reconciliation provides a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.

 

 

 
CONMED News Release ContinuedPage 10 of 12July 24, 2013

 

 

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA

(in thousands)

(unaudited)

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2012   2013   2012   2013 
                 
Net income  $10,296   $9,533   $20,264   $20,025 
                     
Provision for income taxes   5,211    4,736    10,828    8,485 
                     
Interest expense   1,551    1,383    2,988    2,749 
                     
Loss on early extinguishment of debt   —    —    —    263 
                     
Depreciation   4,586    4,549    9,274    9,168 
                     
Amortization   6,459    7,389    13,423    14,381 
                     
EBITDA  $28,103   $27,590   $56,777   $55,071 
                     
Stock-based compensation   1,391    1,344    2,574    2,496 
                     
Facility consolidation costs included in cost of sales   1,202    1,606    2,676    3,228 
                     
Administrative consolidation costs included in other expense   1,231    1,566    1,504    3,170 
                     
Costs associated with purchase of Nordic region distributor   —    —    704    — 
                     
Legal arbitration and patent dispute costs included in other expense   544    527    1,555    736 
                     
Adjusted EBITDA  $32,471   $32,633   $65,790   $64,701 
                     
                     
EBITDA Margin                    
EBITDA   14.8%    14.3%    14.8%    14.5% 
                     
Adjusted EBITDA   17.1%    16.9%    17.1%    17.0% 

 

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.

 

 
CONMED News Release ContinuedPage 11 of 12July 24, 2013

 

CONMED CORPORATION

Second Quarter Sales Summary

(in millions)

 

 

   Three Months Ended June 30, 
                 
               Constant 
               Currency 
   2012   2013   Growth   Growth 
             
Orthopedic surgery  $103.8   $101.8    -1.9%    -1.1% 
General surgery   71.6    73.2    2.2%    2.7% 
Surgical visualization   14.3    18.0    25.9%    25.2% 
   $189.7   $193.0    1.7%    2.3% 
                     
Single-use products  $153.6   $153.8    0.1%    0.7% 
Capital products   36.1    39.2    8.6%    9.2% 
   $189.7   $193.0    1.7%    2.3% 

 

 

 
CONMED News Release ContinuedPage 12 of 12July 24, 2013

CONMED CORPORATION

Six Months Sales Summary

(in millions)

 

 

   Six Months Ended June 30, 
                 
               Constant 
               Currency 
   2012   2013   Growth   Growth 
             
Orthopedic surgery  $210.7   $206.9    -1.8%    -1.2% 
General surgery   141.0    140.0    -0.7%    -0.4% 
Surgical visualization   32.3    33.1    2.5%    3.1% 
   $384.0   $380.0    -1.0%    -0.5% 
                     
Single-use products  $307.2   $301.6    -1.8%    -1.3% 
Capital products   76.8    78.4    2.1%    2.6% 
   $384.0   $380.0    -1.0%    -0.5%